Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and over 35% do not benefit from triptans administration. Serotonin-1F receptors have been identified in trigeminal system and became an ideal target for anti-migraine drug development as potential trigeminal neural inhibitors. Lasmiditan, a novel serotonin1F receptor agonist, showed specific affinity in vitro for the receptor without any vasoconstrictive action and inhibited markers associated with electrical stimulation of trigeminal ganglion in migraine animal models. Areas covered: This article reviews both preclinical and clinical studies on lasmiditan as a potential acute therapy for migraine, as well as pharmacokinetic and pharmacodynamic features. It also summarizes safety and tolerability data gathered in the various human studies. Expert opinion: The absence of vasoconstrictive effects makes lasmiditan a promising novel migraine acute therapy. Although preclinical and Phase I and II studies established a significant efficacy, the limited knowledge about pharmacokinetics and metabolism, the high rate of non-serious central nervous system side effects and the lack of larger studies remain still a matter of concern that should be addressed in future studies.

Lasmiditan for the treatment of migraine / Capi, Matilde; de Andrés, Fernando; Lionetto, Luana; Gentile, Giovanna; Cipolla, Fabiola; Negro, Andrea; Borro, Marina; Martelletti, Paolo; Curto, Martina. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - ELETTRONICO. - 26:2(2017), pp. 227-234. [10.1080/13543784.2017.1280457]

Lasmiditan for the treatment of migraine

GENTILE, Giovanna;NEGRO, ANDREA;BORRO, Marina;MARTELLETTI, Paolo;CURTO, MARTINA
2017

Abstract

Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and over 35% do not benefit from triptans administration. Serotonin-1F receptors have been identified in trigeminal system and became an ideal target for anti-migraine drug development as potential trigeminal neural inhibitors. Lasmiditan, a novel serotonin1F receptor agonist, showed specific affinity in vitro for the receptor without any vasoconstrictive action and inhibited markers associated with electrical stimulation of trigeminal ganglion in migraine animal models. Areas covered: This article reviews both preclinical and clinical studies on lasmiditan as a potential acute therapy for migraine, as well as pharmacokinetic and pharmacodynamic features. It also summarizes safety and tolerability data gathered in the various human studies. Expert opinion: The absence of vasoconstrictive effects makes lasmiditan a promising novel migraine acute therapy. Although preclinical and Phase I and II studies established a significant efficacy, the limited knowledge about pharmacokinetics and metabolism, the high rate of non-serious central nervous system side effects and the lack of larger studies remain still a matter of concern that should be addressed in future studies.
2017
5-HT1F receptor; migraine; acute treatment; clinical trials; lasmiditan
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Lasmiditan for the treatment of migraine / Capi, Matilde; de Andrés, Fernando; Lionetto, Luana; Gentile, Giovanna; Cipolla, Fabiola; Negro, Andrea; Borro, Marina; Martelletti, Paolo; Curto, Martina. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - ELETTRONICO. - 26:2(2017), pp. 227-234. [10.1080/13543784.2017.1280457]
File allegati a questo prodotto
File Dimensione Formato  
Capi_Lasmiditan_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.22 MB
Formato Adobe PDF
1.22 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/926754
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 34
social impact